ProCE Banner Activity

CE

Hit the Ground Running in Crohn’s Disease: A Managed Care Guide to Advanced Biologic Therapies and Early Interventions to Improve Long-term Outcomes

Video

On-demand webcast of expert faculty presentation and patient case discussion in screening and managing Crohn’s disease through early intervention and advanced therapies for managed care professionals.

Pharmacists: 1.50 contact hours (0.15 CEUs)

Released: April 30, 2025

Expiration: April 29, 2026

Share

Provided by

Provided by ProCE, LLC

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Target Audience

The target audience for this activity is population health decision-makers involved in the care of patients with CD, comprising managed care pharmacists, payers, pharmacy benefit managers, and key managed care pharmacy stakeholders, pharmacy directors, chief pharmacy officers, and other managed care professionals, as well as members of integrated delivery systems, such as specialty pharmacists.

Program Learning Goal

The goal of this activity is to improve knowledge and competence of learners regarding their understanding of the latest efficacy and safety data for selective IL-23 inhibitors for Crohn’s disease and the application of these data to managed care decision-making to facilitate prompt treatment initiation and improve patient outcomes.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Analyze the safety and efficacy data informing the use of selective IL-23 inhibitors in moderate to severe CD.

  • Identify managed care considerations that incorporate evidence-based data on novel biologic therapies into formulary decisions and pathway development to prevent delays in therapy and improve clinical outcomes in the management of moderate to severe CD.

  • Assess the contribution of suboptimal therapy to healthcare utilization and costs for patients with moderate to severe CD.

Disclosure

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE, LLC policy. ProCE, LLC is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Bincy P. Abraham, MD, MS, AGAF, FACG, FASGE, FCCF: consultant/advisor/speaker: AbbVie, Celltrion, Janssen, Lilly, Pfizer, Takeda.

David Choi, PharmD, BCACP: consultant/advisor/speaker: AbbVie, Bristol Myers Squibb, Janssen, Lilly, Pfizer.

Sheena K. Crosby, PharmD, BCGP: consultant/advisor/speaker: Pharmacosmos.

The planners and content peer reviewers from ProCE, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 30, 2025, through April 29, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

CE Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-25-004-H01-P has been assigned to this home study application-based activity. This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 65% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.